21.02.2017 22:03:00

Sangamo Therapeutics Announces Fourth Quarter And Full Year 2016 Conference Call And Webcast

RICHMOND, Calif., Feb. 21, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, announced today that the company will release its fourth quarter and full year 2016 financial results before the market opens on Tuesday, February 28, 2017. The press release will be followed by a conference call at 8:30 a.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review its financial results and provide a business update.

The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. The conference ID number for the call is 59818448. Participants may access the live webcast via a link on the Sangamo Therapeutics website in the Investors Relations section under Events and Presentations. A conference call replay will be available for one week following the conference call. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 59818448.

About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. For more information about Sangamo, visit the Company's website at www.sangamo.com.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sangamo-therapeutics-announces-fourth-quarter-and-full-year-2016-conference-call-and-webcast-300410931.html

SOURCE Sangamo Therapeutics, Inc.

Analysen zu Sangamo Therapeutics Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Sangamo Therapeutics Inc 2,60 2,76% Sangamo Therapeutics Inc